CYTK Cytokinetics Incorporated

12.13
-0.01  -0%
Previous Close 12.14
Open 12.05
Price To Book -35.69
Market Cap 717,919,184
Shares 59,161,037
Volume 791,422
Short Ratio
Av. Daily Volume 1,078,069
Stock charts supplied by TradingView

NewsSee all news

  1. Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones

    Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway REDWOOD-HCM Initiated; Second Cardiac Myosin Inhibitor Planned to Enter Clinic in 1H 2020 SOUTH SAN FRANCISCO, Calif., Jan. 13,

  2. Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in

  3. Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis

    SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to

  4. Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that new results were presented at the 30th International Symposium on ALS/MND in Perth,

  5. Cytokinetics to Participate in the Piper Jaffray Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research & Development, is

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated in 2020.
Reldesemtiv
Amyotrophic lateral sclerosis (ALS)
Phase 1b interim analysis noted lack of efficacy.
CK-2127107
Limited mobility
Phase 3 second interim analysis due 1Q 2020. Top-line data due 4Q 2020.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 3 data released November 21, 2017 - primary endpoint not met.
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 2 data did not meet endpoints - October 5, 2018.
Reldesemtiv (CK-2127107)
Chronic obstructive pulmonary disease (COPD)
Second Phase 3 trial initiation announced February 21, 2019. Enrolment to continue through 2020.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 2 trial initiation announced January 6, 2020.
CK-3773274 - Redwood-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 1 trial to be completed 2H 2020.
AMG 594
Healthy volunteers

Latest News

  1. Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones

    Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway REDWOOD-HCM Initiated; Second Cardiac Myosin Inhibitor Planned to Enter Clinic in 1H 2020 SOUTH SAN FRANCISCO, Calif., Jan. 13,

  2. Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in

  3. Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis

    SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to

  4. Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that new results were presented at the 30th International Symposium on ALS/MND in Perth,

  5. Cytokinetics to Participate in the Piper Jaffray Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research & Development, is

  6. Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced five poster presentations at the 30th International Symposium on ALS/MND in Perth, Australia. The

  7. New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function

    THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France,, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier announced that new results from

  8. Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2019

    SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase

  9. Cytokinetics Announces Pricing of Public Offering of Convertible Senior Notes

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it has agreed to sell an aggregate of $120.0 million principal amount of its 4.00%

  10. Cytokinetics Announces Proposed Public Offering of Convertible Senior Notes

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it expects to sell, subject to market and other conditions, an aggregate of $100.0 million

  11. Cytokinetics to Participate in the Credit Suisse 28th Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research & Development, is

  12. Cytokinetics Reports Third Quarter 2019 Financial Results

    Enrollment Completed in GALACTIC-HF with More than 8,200 Heart Failure Patients; Second Interim Analysis Expected in Q1 2020 Data from Phase 1 Study of CK-274 Support Progression; Phase 2 Clinical Trial in Patients with

  13. Cytokinetics to Announce Third Quarter Results on October 31, 2019

    SOUTH SAN FRANCISCO, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report third quarter results on October 31, 2019 at 4:00 PM Eastern Time.

  14. Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting

    SOUTH SAN FRANCISCO, Calif., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced additional analyses of FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational

  15. Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate

  16. Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial

  17. Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals

    Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular or Neuromuscular Diseases Deadline for Applications is November 15th, 2019 SOUTH SAN FRANCISCO, Calif., Sept. 25,

  18. Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23ʳᵈ Annual Scientific Meeting

    Pharmacokinetic/Pharmacodynamic Relationship in Humans Similar to Preclinical Findings  Data Support Progression to Phase 2 Clinical Trial in Patients with Obstructive Hypertrophic Cardiomyopathy to Begin in Q4 2019

  19. Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting

    SOUTH SAN FRANCISCO, Calif., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced two poster presentations at the 23rd Annual Heart Failure Society of America (HFSA) Scientific

  20. Cytokinetics to Present at September Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate

  21. Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA

    ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics (NASDAQ:CYTK) today announced the renewal of their partnership to increase education, awareness,